Skip to main content
. 2023 Jun 7;13:9257. doi: 10.1038/s41598-023-33876-8

Figure 1.

Figure 1

Trough dabigatran (assessed by in-home diluted thrombin time), rivaroxaban and apixaban (assessed with anti-Xa assays) concentrations in patients on concomitant treatment with levetiracetam (black circles for patients with atrial fibrillation and grey circles for two patients with venous thromboembolism). Measured concentrations are related to exposure trough concentrations in patients with atrial fibrillation not treated with levetiracetam (empty circles) obtained from our previous studies1517.